# Azienda Ospedaliera S.Giuseppe Moscati

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/azienda-ospedaliera-s-giuseppe-moscati/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 68 |
| Citations | 113,135 |
| City | Avellino |
| Country | IT |
| Description | Azienda Ospedaliera S.Giuseppe Moscati is a research organisation in Avellino, IT. OpenAlex records 3,390 works and 113,135 citations for it. 745 researchers list it as their most recent affiliation. |
| Homepage | http://www.aosgmoscati.av.it/ |
| OpenAlex ID | https://openalex.org/I4210111929 |
| Researchers | 745 |
| ROR ID | https://ror.org/021jxzw96 |
| Type | healthcare |
| Works | 3,390 |

## University papers

- [Non-small-cell lung cancer](https://scholariq.org/papers/non-small-cell-lung-cancer/)
- [Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-i-alk-i-positive-non-small-cell-lung-cancer/)
- [Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/ceritinib-versus-chemotherapy-in-patients-with-alk-rearranged-non-small-cell/)
- [Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data](https://scholariq.org/papers/carboplatin-or-cisplatin-based-chemotherapy-in-first-line-treatment-of-small/)
- [Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study](https://scholariq.org/papers/pretreatment-quality-of-life-and-functional-status-assessment-significantly/)
- [First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial](https://scholariq.org/papers/first-line-erlotinib-followed-by-second-line-cisplatin-gemcitabine-chemotherapy/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [Complement system in diseases](https://scholariq.org/topics/complement-system-in-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.